Brind.

Analysis Compares DBV Technologies and Equillium as Small-Cap Healthcare Stocks

2 reports, 1 independent Updated Sep 21
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Equillium and DBV Technologies are both classified as small-cap healthcare companies. An analysis comparing the two firms noted that DBV Technologies has a consensus target price of $48.50, while Equillium's target price is $7.57. Analysts indicated that DBV Technologies is more favorable due to its higher probable upside.

From dailypolitical.com

Why it matters

Some supportBrind's analysis of the reports

The comparison highlights significant differences in market perception and risk profiles between the two firms. DBV Technologies has substantially higher institutional ownership (71.7%) compared to Equillium (27.1%). Furthermore, DBV Technologies exhibits a negative beta of -0.95, suggesting lower volatility than Equillium's beta of 1.81.

From dailypolitical.com

Who's involved

  • DBV TechnologiesFrench biopharmaceutical firm subject to market analysis
  • MarketBeatAmerican personal finance blog providing consensus ratings

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story